Edwards Lifesciences Corporation (EW) is a leading medical devices business based in the US. Edwards Lifesciences Corporation is listed on the NYSE and employs 13,900 staff. All prices are listed in US Dollars.
|52-week range||$51.5067 - $92.08|
|50-day moving average||$87.5027|
|200-day moving average||$81.5104|
|Wall St. target price||$94.35|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$1.265|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Edwards Lifesciences Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Edwards Lifesciences Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Edwards Lifesciences Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 68x. In other words, Edwards Lifesciences Corporation shares trade at around 68x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Edwards Lifesciences Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.2397. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Edwards Lifesciences Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Edwards Lifesciences Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $1.4 billion.
The EBITDA is a measure of a Edwards Lifesciences Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$4.4 billion|
|Operating margin TTM||29.85%|
|Gross profit TTM||$3.2 billion|
|Return on assets TTM||12.77%|
|Return on equity TTM||19.79%|
|Market capitalisation||$53.3 billion|
TTM: trailing 12 months
There are currently 4.6 million Edwards Lifesciences Corporation shares held short by investors – that's known as Edwards Lifesciences Corporation's "short interest". This figure is 12.9% down from 5.3 million last month.
There are a few different ways that this level of interest in shorting Edwards Lifesciences Corporation shares can be evaluated.
Edwards Lifesciences Corporation's "short interest ratio" (SIR) is the quantity of Edwards Lifesciences Corporation shares currently shorted divided by the average quantity of Edwards Lifesciences Corporation shares traded daily (recently around 2.2 million). Edwards Lifesciences Corporation's SIR currently stands at 2.09. In other words for every 100,000 Edwards Lifesciences Corporation shares traded daily on the market, roughly 2090 shares are currently held short.
However Edwards Lifesciences Corporation's short interest can also be evaluated against the total number of Edwards Lifesciences Corporation shares, or, against the total number of tradable Edwards Lifesciences Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Edwards Lifesciences Corporation's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Edwards Lifesciences Corporation shares in existence, roughly 10 shares are currently held short) or 0.0076% of the tradable shares (for every 100,000 tradable Edwards Lifesciences Corporation shares, roughly 8 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Edwards Lifesciences Corporation.
Find out more about how you can short Edwards Lifesciences Corporation stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Edwards Lifesciences Corporation.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 21.68
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Edwards Lifesciences Corporation's overall score of 21.68 (as at 01/01/2019) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Edwards Lifesciences Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.78/100
Edwards Lifesciences Corporation's environmental score of 4.78 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 13.43/100
Edwards Lifesciences Corporation's social score of 13.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 10.96/100
Edwards Lifesciences Corporation's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Edwards Lifesciences Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Edwards Lifesciences Corporation scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Edwards Lifesciences Corporation has, for the most part, managed to keep its nose clean.
|Total ESG score||21.68|
|Total ESG percentile||24.1|
|Environmental score percentile||6|
|Social score percentile||6|
|Governance score percentile||6|
|Level of controversy||2|
We're not expecting Edwards Lifesciences Corporation to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Edwards Lifesciences Corporation's shares were split on a 3:1 basis on 1 June 2020. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Edwards Lifesciences Corporation shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Edwards Lifesciences Corporation shares which in turn could have impacted Edwards Lifesciences Corporation's share price.
Over the last 12 months, Edwards Lifesciences Corporation's shares have ranged in value from as little as $51.5067 up to $92.08. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Edwards Lifesciences Corporation's is 0.9732. This would suggest that Edwards Lifesciences Corporation's shares are less volatile than average (for this exchange).
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral valve diseases, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.